(64)Cu-ATSM therapy targets regions with activated DNA repair and enrichment of CD133(+) cells in an HT-29 tumor model: Sensitization with a nucleic acid antimetabolite.

doi:10.1016/j.canlet.2016.03.020

Article

(64)Cu-ATSM therapy targets regions with activated DNA repair and enrichment of CD133(+) cells in an HT-29 tumor model: Sensitization with a nucleic acid antimetabolite.

Cancer letters - 28 Jun 2016

Yoshii Yukie, Furukawa Takako, Matsumoto Hiroki, Yoshimoto Mitsuyoshi, Kiyono Yasushi, Zhang Ming-Rong, Fujibayashi Yasuhisa, Saga Tsuneo

Abstract excerpt

(64)Cu-diacetyl-bis (N(4)-methylthiosemicarbazone) ((64)Cu-ATSM) is a potential theranostic agent targeting the over-reduced state under hypoxia within tumors. Recent clinical Cu-ATSM positron emission tomography studies have revealed a correlation between uptake and poor prognosis; however, the reason is unclear. Here, using a human colon carcinoma HT-29 model, we demonstrated that the intratumoral (64)Cu-ATSM...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

(64)Cu-ATSM therapy targets regions with activated DNA repair and enrichment of CD133(+) cells in an HT-29 tumor model: Sensitization with a nucleic acid antimetabolite.

Abstract excerpt

Topics

Related research